Elite in IgG4-Related Disease

Emma L. Culver

Oxford, ENG, GB 
Elite in IgG4-Related Disease
Oxford, ENG, GB 
OverviewLocationsClinical Research

Overview

Emma Culver practices in Oxford, United Kingdom. Ms. Culver is rated as an Elite expert by MediFind in the treatment of IgG4-Related Disease. Her top areas of expertise are IgG4-Related Disease, Cholangitis, Sclerosing Cholangitis, Endoscopy, and Colonoscopy.

Her clinical research consists of co-authoring 81 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 22 articles in the study of IgG4-Related Disease.

Gender
Female

Locations

Oxford, ENG, United Kingdom
Other Locations
Pond Street, London, ENG NW32QG, United Kingdom
Reading, ENG, United Kingdom
High Wycombe, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drugs: Obeticholic Acid, Bezafibrate
Study Phase: Phase 2
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
View 1 Less Clinical Trial

81 Total Publications

Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model.
Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Culver's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile